FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation
Authors:
- 16 February 2017
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (4) , 2391-2397
Abstract
Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ. Although several mechanisms underlying GBM resistance to TMZ have been identified, these mechanisms are yet to fully explain how GBM gains resistance to TMZ. Our previous work has shown that FoxO3a, a member of the FoxO subfamily of transcription factors, promotes glioma cell proliferation and invasion. In this study, we sought to determine whether FoxO3a participates in TMZ resistance in GBM cells. Parental cell lines (also designated as sensitive cell lines) U87-MG and U251-MG, as well as the corresponding resistant cell lines U87-TR and U251-TR (generated by repeated TMZ treatments), were subjected to western blot analysis. Our results showed that the resistant cells (both U87-TRand U251-TR) exhibited higher levels of FoxO3a and β-catenin relative to their corresponding sensitive counterparts. Depletion of FoxO3a in the resistant cells enhanced the cytotoxic effect of TMZ. Further investigation showed that FoxO3a depletion did not affect the total protein level of β-catenin, but otherwise markedly reduced the nuclear β-catenin level. Taken together, these findings strongly support that FoxO3a renders GBM cells resistant to TMZ treatment, at least in part, through the regulation of β-catenin nuclear accumulation.Keywords
This publication has 36 references indexed in Scilit:
- Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsJournal of Clinical Investigation, 2012
- Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma CellsJournal of Biomedicine and Biotechnology, 2012
- β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and ChemoresistancePLOS ONE, 2011
- Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast CancerPLOS ONE, 2010
- FOXO3a Promotes Tumor Cell Invasion through the Induction of Matrix MetalloproteinasesMolecular and Cellular Biology, 2009
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide ResistanceClinical Cancer Research, 2009
- Wnt1 overexpression promotes tumour progression in non-small cell lung cancerEuropean Journal of Cancer, 2008
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaClinical Cancer Research, 2008
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005